title: Hybrid drug delivery system for oropharyngeal, cervical and colorectal cancer - in vitro and in vivo evaluation.
abstract: The present investigation was designed with the intention to formulate a versatile 5-fluorouracil(5-FU) matrix tablet surpassing issues associated with current conventional chemotherapeutic drug delivery systems. The novel 5-FU matrix tablet fulfills therapeutic needs by engineering matrix tablets utilizing chitosan-sodium alginate interpolyelectrolyte complex (IPEC). IPEC was characterized by Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and X-ray diffraction (XRD). The matrix tablets were formulated utilizing IPEC alone and in combination with chitosan, sodium alginate and sodium deoxycholate as permeation enhancer. Pharmaceutical properties, swelling studies, in vitro dissolution and diffusion studies, mucoadhesive studies and in vivo studies were performed for formulated 5-FU. The selected chitosan-sodium alginate IPEC offers pH independent 5-FU release in comparison to alone or physical mixture of chitosan and sodium alginate. Furthermore, novel matrix tablets demonstrated significantly higher bioadhesive properties with controlled 5-FU release without the initial burst effect and also demonstrated a higher permeation of 5-FU. To conclude, the developed novel 5-FU matrix tablets pave way as an excellent alternative for cancer treatment which could potentially minimize the dose dependent side effects and provide better patient compliance.
authors: Dept of Pharmaceutics, JSS College of Pharmacy, JSS University, SS Nagar, Mysore 15, Karnataka, India.
authors: Mohamed S
authors: MS
authors: Pendekal
authors: Pramod K
authors: PK
authors: Tegginamat
keywords: Buccal pH; Chitosan; Interpolyelectrolyte complex; Rectal pH; Sodium alginate; Vaginal pH
references: Biomaterials. 2005 Jun;26(18):3919-28
references: 15626439
references: Eur J Pharm Biopharm. 2007 Feb;65(2):215-32
references: 16982178
references: Biopolymers. 2006 Jun 5;82(2):176-87
references: 16489584
references: J Control Release. 2005 Mar 2;103(1):191-8
references: 15710510
references: Int J Pharm. 2005 Jul 14;298(1):98-107
references: 15913928
references: Biopolymers. 2006 Aug 15;82(6):570-9
references: 16552738
references: Pharm Dev Technol. 2008;13(1):15-25
references: 18300096
references: Biomacromolecules. 2004 May-Jun;5(3):828-33
references: 15132668
references: Biomaterials. 1999 Jun;20(12):1133-42
references: 10382829
references: J Control Release. 2003 Nov 18;93(1):1-13
references: 14602417
references: Curr Drug Deliv. 2010 Apr;7(2):109-17
references: 20158481
references: J Control Release. 2006 Aug 10;114(1):1-14
references: 16828914
references: Adv Drug Deliv Rev. 1998 May 4;31(3):267-285
references: 10837629
references: Eur J Pharm Biopharm. 2004 Jan;57(1):19-34
references: 14729078
references: Colloids Surf B Biointerfaces. 2006 Dec 1;53(2):193-202
references: 17049214
references: Clin Pharmacokinet. 1989 Apr;16(4):215-37
references: 2656050
references: Adv Drug Deliv Rev. 2006 Jul 7;58(4):487-99
references: 16762443
references: Carbohydr Res. 2005 Nov 21;340(16):2510-9
references: 16168971
references: Pharm Res. 1991 Jan;8(1):17-24
references: 2014203
references: Macromol Biosci. 2006 Aug 7;6(8):623-33
references: 16881042
references: Biomacromolecules. 2007 Aug;8(8):2533-41
references: 17591747
references: Eur J Pharm Sci. 2004 Nov;23(3):261-70
references: 15489127